|Day's range||0.3500 - 0.5900|
The past 15 months haven't been easy for growth stock investors. The Nasdaq Composite index has fallen a disappointing 25% since the beginning of 2022, making this an unusually long bear market. You don't need an economics degree to see that every bear market in history has been wiped away by subsequent recoveries.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.